Multivariate analysis of factors associated with GVHD, relapse, and TRM in patients undergoing myeloablative unrelated donor PBSC transplantation
| Variable . | n . | RR (95% CI) . | P . |
|---|---|---|---|
| Grades II-IV acute GVHD | |||
| GVHD prophylaxis | |||
| CsA-based | 337 | 1.00 | |
| FK506-based | 260 | 0.68 (0.54-0.85) | < .001 |
| Grades III-IV acute GVHD | |||
| HLA matching status | .001 | ||
| Well-matched | 345 | 1.00 | |
| Partially matched | 173 | 1.57 (1.13-2.19) | .007 |
| Mismatched | 79 | 1.93 (1.29-2.88) | .001 |
| Chronic GVHD | |||
| GVHD prophylaxis | |||
| CsA-based | 342 | 1.00 | |
| FK506-based | 260 | 0.59 (0.46-0.75) | < .001 |
| Conditioning regimen | |||
| Non-TBI | 209 | 1.00 | |
| TBI | 393 | 0.72 (0.57-0.91) | .007 |
| Year of transplantation | |||
| 1999-2000 | 95 | 1.00 | |
| 2001 | 126 | 1.28 (0.88-1.87) | .193 |
| 2002 | 158 | 1.55 (1.08-2.23) | .018 |
| 2003 | 223 | 1.70 (1.21-2.40) | .002 |
| Relapse | |||
| Disease | < .001 | ||
| AML | 238 | 1.00 | |
| ALL | 157 | 0.83 (0.56-1.23) | .348 |
| CML | 93 | 0.18 (0.07-0.46) | < .001 |
| MDS | 107 | 0.43 (0.25-0.73) | .002 |
| Disease risk | < .001 | ||
| Early | 203 | 1.00 | |
| Intermediate | 210 | 2.17 (1.33-3.54) | .002 |
| Advanced | 182 | 3.72 (2.33-5.93) | < .001 |
| Transplant-related mortality | |||
| HLA matching status | < .001 | ||
| Well-matched | 348 | 1.00 | |
| Partially matched | 169 | 1.47 (1.12-1.92) | .005 |
| Mismatched | 76 | 2.30 (1.63-3.26) | < .001 |
| CD34+ cells dose, ×106/kg | .031 | ||
| 4.5 or less | 138 | 1.00 | |
| More than 4.5 | 287 | 0.68 (0.50-0.92) | .013 |
| Missing | 170 | 0.89 (0.64-1.23) | .472 |
| Karnofsky score | < .001 | ||
| 90-100 | 362 | 1.00 | |
| 10-80 | 177 | 1.83 (1.41-2.37) | < .001 |
| Missing | 56 | 0.94 (0.57-1.54) | .799 |
| GVHD prophylaxis | |||
| CsA-based | 339 | 1.00 | |
| FK506-based | 256 | 1.51 (1.18-1.93) | .001 |
| Variable . | n . | RR (95% CI) . | P . |
|---|---|---|---|
| Grades II-IV acute GVHD | |||
| GVHD prophylaxis | |||
| CsA-based | 337 | 1.00 | |
| FK506-based | 260 | 0.68 (0.54-0.85) | < .001 |
| Grades III-IV acute GVHD | |||
| HLA matching status | .001 | ||
| Well-matched | 345 | 1.00 | |
| Partially matched | 173 | 1.57 (1.13-2.19) | .007 |
| Mismatched | 79 | 1.93 (1.29-2.88) | .001 |
| Chronic GVHD | |||
| GVHD prophylaxis | |||
| CsA-based | 342 | 1.00 | |
| FK506-based | 260 | 0.59 (0.46-0.75) | < .001 |
| Conditioning regimen | |||
| Non-TBI | 209 | 1.00 | |
| TBI | 393 | 0.72 (0.57-0.91) | .007 |
| Year of transplantation | |||
| 1999-2000 | 95 | 1.00 | |
| 2001 | 126 | 1.28 (0.88-1.87) | .193 |
| 2002 | 158 | 1.55 (1.08-2.23) | .018 |
| 2003 | 223 | 1.70 (1.21-2.40) | .002 |
| Relapse | |||
| Disease | < .001 | ||
| AML | 238 | 1.00 | |
| ALL | 157 | 0.83 (0.56-1.23) | .348 |
| CML | 93 | 0.18 (0.07-0.46) | < .001 |
| MDS | 107 | 0.43 (0.25-0.73) | .002 |
| Disease risk | < .001 | ||
| Early | 203 | 1.00 | |
| Intermediate | 210 | 2.17 (1.33-3.54) | .002 |
| Advanced | 182 | 3.72 (2.33-5.93) | < .001 |
| Transplant-related mortality | |||
| HLA matching status | < .001 | ||
| Well-matched | 348 | 1.00 | |
| Partially matched | 169 | 1.47 (1.12-1.92) | .005 |
| Mismatched | 76 | 2.30 (1.63-3.26) | < .001 |
| CD34+ cells dose, ×106/kg | .031 | ||
| 4.5 or less | 138 | 1.00 | |
| More than 4.5 | 287 | 0.68 (0.50-0.92) | .013 |
| Missing | 170 | 0.89 (0.64-1.23) | .472 |
| Karnofsky score | < .001 | ||
| 90-100 | 362 | 1.00 | |
| 10-80 | 177 | 1.83 (1.41-2.37) | < .001 |
| Missing | 56 | 0.94 (0.57-1.54) | .799 |
| GVHD prophylaxis | |||
| CsA-based | 339 | 1.00 | |
| FK506-based | 256 | 1.51 (1.18-1.93) | .001 |